Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Medigene AG
  6. Summary
    MDG1   DE000A1X3W00

MEDIGENE AG

(MDG1)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 08/03 03:11:50 am
3.963 EUR   -0.43%
07/01MEDIGENE : Participates at upcoming conferences
AQ
06/24MEDIGENE : reports on Annual General Meeting 2021
PU
06/24MEDIGENE : AGM 2021 Management presentation
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
4.02(c) 3.92(c) 4.01(c) 3.92(c) 3.98(c) Last
11 251 10 742 8 849 12 355 3 626 Volume
+2.03% -2.49% +2.30% -2.24% +1.53% Change
More quotes
Estimated financial data (e)
Sales 2021 7,87 M 9,34 M 9,34 M
Net income 2021 -16,7 M -19,8 M -19,8 M
Net cash position 2021 10,1 M 12,0 M 12,0 M
P/E ratio 2021 -5,97x
Yield 2021 -
Sales 2022 29,1 M 34,5 M 34,5 M
Net income 2022 -25,4 M -30,2 M -30,2 M
Net cash position 2022 0,58 M 0,69 M 0,69 M
P/E ratio 2022 -4,36x
Yield 2022 -
Capitalization 97,8 M 116 M 116 M
EV / Sales 2021 11,1x
EV / Sales 2022 3,34x
Nbr of Employees 114
Free-Float 89,6%
More Financials
Company
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens;... 
More about the company
Ratings of Medigene AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MEDIGENE AG
07/01MEDIGENE : Participates at upcoming conferences
AQ
06/24MEDIGENE : reports on Annual General Meeting 2021
PU
06/24MEDIGENE : AGM 2021 Management presentation
PU
06/24MEDIGENE : Company presentation
PU
06/24MEDIGENE : Unternehmenspräsentation
PU
06/09MEDIGENE : presents compelling in vivo data for use of PD1-41BB-enhanced TCR-T c..
PU
05/11MEDIGENE : provides Q1 2021 update
PU
05/11Medigene AG Provides Earnings Guidance for the Year 2021
CI
05/10MEDIGENE : presents new data on components of solid cancer TCR-T therapies at CI..
PU
05/10Medigene AG Presents New Data on Components of Solid Cancer TCR-T Therapies a..
CI
04/10MEDIGENE : Identification of ten novel tumor-specific antigens immunogenic for T..
PU
04/10MEDIGENE : AACR data show characteristics of Medigene's lead TCR candidate again..
PU
04/07MEDIGENE : Participation at upcoming virtual conferences
PU
03/31BLUEBIRD BIO : Medigene AG - Publication of research on co-receptor independent ..
AQ
03/30MEDIGENE : Publication of research on co-receptor independent MAGE-A4-specific T..
PU
More news
News in other languages on MEDIGENE AG
07/12Aktien Frankfurt: Dax mit verhaltenem Wochenstart nach Freitagsrally
07/12Aktien Frankfurt: Dax mit trägem Start nach starkem Wochenausklang
07/12Aktien Frankfurt Eröffnung: Dax nach Freitagsgewinnen träge
07/12OPINIONES DE LOS ANALISTAS DEL DÍA : Randstad, Sensirion, Givaudan, Kion, Medige..
07/12MADRID STOCK EXCHANGE : Atención, ísemana ocupada!
More news
Analyst Recommendations on MEDIGENE AG
More recommendations
Chart MEDIGENE AG
Duration : Period :
Medigene AG Technical Analysis Chart | MDG1 | DE000A1X3W00 | MarketScreener
Technical analysis trends MEDIGENE AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 3,98 €
Average target price 8,60 €
Spread / Average Target 116%
EPS Revisions
Managers and Directors
Dolores J. Schendel Chief Executive & Scientific Officer
Axel-Sven Malkomes Chief Financial & Business Development Officer
Gerd Zettlmeissl Chairman-Supervisory Board
Antoinette Hiebeler-Hasner Deputy Chairman-Supervisory Board
Ronald Scott Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
MEDIGENE AG13.07%116
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.03%47 462
CELLTRION, INC.-26.60%30 059
SEAGEN INC.-11.93%27 907